Clinical Trials Logo

Filter by:
NCT ID: NCT01106677 Completed - Clinical trials for Diabetes Mellitus, Type 2

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

Start date: May 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e., treatment with a single drug) and have inadequate glycemic (blood sugar) control.

NCT ID: NCT01104753 Completed - Ulcerative Colitis Clinical Trials

A Study of Pentasa in Patients With Ulcerative Colitis

Start date: September 2009
Phase: N/A
Study type: Observational

Confirmation of safety profile of Pentasa slow release tablets 500 mg in patients with ulcerative colitis (UC).

NCT ID: NCT01103323 Completed - Clinical trials for Metastatic Colorectal Cancer

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Start date: April 2010
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC

NCT ID: NCT01103284 Active, not recruiting - Clinical trials for Type 1 Diabetes Mellitus

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

DIA-AID2
Start date: April 2010
Phase: Phase 3
Study type: Interventional

This study will look at the treatment effect of DiaPep277 on preservation of beta-cell function, as defined by meal-stimulated secretion of insulin. DiaPep277 is a peptide that changes the way the immune system behaves, stopping its attack on the beta-cells. Adults (>20 years) with newly diagnosed (<6 months) type 1 diabetes will be treated with 10 injections of DiaPep277 or Placebo over a 2-year treatment and follow-up period.

NCT ID: NCT01098487 Completed - Clinical trials for Purpura, Thrombocytopaenic, Idiopathic

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Start date: May 2010
Phase: Phase 4
Study type: Interventional

A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term effect of eltrombopag on bone marrow fibers. The study will also describe the long-term safety and tolerability of oral eltrombopag treatment in subjects with chronic ITP.

NCT ID: NCT01095081 Completed - Clinical trials for Magnetic Resonance Imaging

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients

GARDIAN
Start date: July 2010
Phase: N/A
Study type: Observational

Prospective, non-interventional, multi-center study. The observation period for each subject covers the treatment period with Gadovist®. For each patient, the treating physician or nurse documents demographics, medical data, safety parameters and treatment signs and symptoms at the visit. Patients with severe renal impairment will be followed-up after 3 month by phone call from the investigator if in line with routine practice. Data audit/monitoring by source data verification will be done in a subset of sites and patients

NCT ID: NCT01093534 Completed - Overactive Bladder Clinical Trials

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

SHRINK
Start date: January 2010
Phase: Phase 4
Study type: Interventional

The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.

NCT ID: NCT01092832 Terminated - Candidiasis Clinical Trials

A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients

Start date: October 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether voriconazole is safe and effective for the treatment of serious Candida infection and Candida infection of the esophagus in children and adolescents.

NCT ID: NCT01091662 Completed - Epilepsy Clinical Trials

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

Start date: June 2010
Phase: Phase 3
Study type: Interventional

This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.

NCT ID: NCT01088451 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 1

Joint Application of Human Insulin and Rapid Insulin Analogue in Control of Postprandial Glycemia

CPIT
Start date: December 2009
Phase: N/A
Study type: Interventional

Postprandial glycemic control is essential for diabetes compensation. Insulin pump therapy control blood glucose released in response to both high and low glycemic index carbohydrates in a mixed diet using normal, square and dual-wave boluses. The investigators hypothesize a mixture of rapid insulin analogue and human insulin has the same effect. This pilot prospective cohort study replaces basal-bolus therapy of diabetic subjects by combined prandial application of insulin aspart and human insulin. Mixed-meals with high, both high and low and low glycemic index carbohydrates are covered by 3:1, 1:1 and 1:3 ratios of analogue to human insulin mixture. Subjects are followed by continuous glucose monitor for six days (Phase One), changing between the experimental or their standard protocol for insulin injection on consecutive days. The outcome was measured by comparing average glycemia and areas under the curve of sample meals, which are doughnut, pizza and mixed vegetable salad. The next three-to-four week period of therapy was evaluated by glycated hemoglobin before and after the intervention (Phase Two). Expected outcomes are postprandial and complex improvement of diabetes control, similarly to the insulin pump therapy.